March 3 (Reuters) - Sierra Oncology Inc SRRA.O :
* SIERRA ONCOLOGY REPORTS 2019 YEAR END RESULTS
* SIERRA ONCOLOGY - ANTICIPATES CURRENT RESOURCES TO BE SUFFICIENT FOR DEVELOPMENT STRATEGY FOR MOMELOTINIB INTO H2 2022
* SIERRA ONCOLOGY INC QTRLY LOSS PER SHARE $7.88
* SIERRA ONCOLOGY INC QTRLY NON-GAAP ADJUSTED LOSS PER SHARE $2.51